<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39311094</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Risk factors for post-coronavirus disease condition in the Alpha-, Delta-, and Omicron-dominant waves among adults in Japan: A population-based matched case-control study.</ArticleTitle><Pagination><StartPage>e29928</StartPage><MedlinePgn>e29928</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29928</ELocationID><Abstract><AbstractText>Vaccination is associated with a reduced risk of post-coronavirus disease (COVID-19) condition (PCC). Here, risk factors including vaccination for PCC in the Omicron-dominant waves among Japanese adults were investigated. This was a registry-based matched case-control study of individuals aged 18-79 years diagnosed with COVID-19 registered in a National database between March 2021 and April 2022 and matched noninfected individuals living in Yao City, Japan. A self-administered questionnaire was used to assess persistent symptoms and their risk factors. The COVID-19 vaccination status was obtained from the Vaccination Registry. PCC risk factors were analyzed using logistic regression after adjusting for potential confounding factors. Overall, 4185 infected (cases) and 3382 noninfected (controls) individuals were included in the analysis. The mean ages and proportions of women were 44.7 years and 60.2% and 45.5 years and 60.7% for cases and controls, respectively. A total of 3805 (90.9%) participants had asymptomatic or mild acute symptoms at the median (range) follow-up of 271 (185-605) days. The prevalence of PCC was 15.0% for cases while that of persistent symptoms was 4.4% for controls; among the cases, it was 27.0% in the Alpha- and Delta-dominant waves and 12.8% in the Omicron-dominant wave. Female sex, comorbidities, and hospitalization were positively associated with PCC. One or more vaccine doses of vaccination were inversely associated with PCC; the inverse association was stronger in the Alpha- and Delta-dominant waves (adjusted odds ratio [aOR]: 0.29, 95% confidence interval [CI]: 0.12-0.73) than in the Omicron-dominant wave (aOR: 0.79, 95% CI: 0.59-1.07).</AbstractText><CopyrightInformation>&#xa9; 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hori</LastName><ForeName>Miyuki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayama-Terada</LastName><ForeName>Mina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Yao City Public Health Center, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitamura</LastName><ForeName>Akihiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Yao City Public Health Center, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosozawa</LastName><ForeName>Mariko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muto</LastName><ForeName>Yoko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iba</LastName><ForeName>Arisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takayama</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Yao City Public Health Center, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Public Health, Faculty of Medicine, Hokkaido University, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iso</LastName><ForeName>Hiroyasu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JPMH21HA2011</GrantID><Agency>This study was supported by the Ministry of Health, Labour and Welfare Research Program on Emerging and Re-emerging Infectious Diseases</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">Japan</Keyword><Keyword MajorTopicYN="N">Post&#x2010;COVID&#x2010;19 condition</Keyword><Keyword MajorTopicYN="N">SARS&#x2010;CoV&#x2010;2</Keyword><Keyword MajorTopicYN="N">long&#x2010;COVID</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39311094</ArticleId><ArticleId IdType="doi">10.1002/jmv.29928</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>World Health Organization. WHO COVID&#x2010;19 Dashboard. 2024. Accessed January 25, 2024. https://covid19.who.int/</Citation></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, et al. A clinical case definition of post COVID&#x2010;19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102&#x2010;e107. doi:10.1016/S1473-3099(21)00703-9</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133&#x2010;146. doi:10.1038/s41579-023-00896-0</Citation></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with Delta versus Omicron variants of SARS&#x2010;CoV&#x2010;2. Lancet. 2022;399:2263&#x2010;2264. doi:10.1016/S0140-6736(22)00941-2</Citation></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Network Open. 2022;5:e2238804. doi:10.1001/jamanetworkopen.2022.38804</Citation></Reference><Reference><Citation>Jassat W, Mudara C, Vika C, et al. A cohort study of post&#x2010;COVID&#x2010;19 condition across the Beta, Delta, and Omicron waves in South Africa: 6&#x2010;month follow&#x2010;up of hospitalized and nonhospitalized participants. Int J Infect Dis. 2023;128:102&#x2010;111. doi:10.1016/j.ijid.2022.12.036</Citation></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV, et al. Impact of COVID&#x2010;19 vaccination on the risk of developing long&#x2010;COVID and on existing long&#x2010;COVID symptoms: a systematic review. EClinicalMedicine. 2022;53:101624. doi:10.1016/j.eclinm.2022.101624</Citation></Reference><Reference><Citation>Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of COVID&#x2010;19 vaccination on long COVID. Syst Rev. BMJ Publishing Group Med. 2023;2:e000385.</Citation></Reference><Reference><Citation>Tsampasian V, Elghazaly H, Chattopadhyay R, et al. Risk factors associated with post&#x2010;COVID&#x2010;19 condition: a systematic review and meta&#x2010;analysis. JAMA Internal Med. 2023;183:566&#x2010;580. doi:10.1001/jamainternmed.2023.0750</Citation></Reference><Reference><Citation>WHO Working Group on the Clinical Characterisation and Management of COVID&#x2010;19 infection. A minimal common outcome measure set for COVID&#x2010;19 clinical research. Lancet Infect Dis. 2020;20:e192&#x2010;e197. doi:10.1016/S1473-3099(20)30483-7</Citation></Reference><Reference><Citation>ISARIC. ISARIC COVID&#x2010;19 follow&#x2010;up study. 2020. Accessed January 25, 2024. https://isaric.org/research/covid-19-clinical-research-resources/covid-19-long-term-follow-up-study-old/</Citation></Reference><Reference><Citation>Ministry of Health, Labour and Welfare. Number of doses of the COVID&#x2010;19 vaccine (in Japanese). 2024. Accessed January 25, https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou/yobou-sesshu/syukeihou_00002.html</Citation></Reference><Reference><Citation>Whitaker M, Elliott J, Chadeau&#x2010;Hyam M, et al. Persistent COVID&#x2010;19 symptoms in a community study of 606,434 people in England. Nat Commun. 2022;13:1957. doi:10.1038/s41467-022-29521-z</Citation></Reference><Reference><Citation>Spudich S, Nath A. Nervous system consequences of COVID&#x2010;19. Science. 2022;375:267&#x2010;269. doi:10.1126/science.abm2052</Citation></Reference><Reference><Citation>Premraj L, Kannapadi NV, Briggs J, et al. Mid and long&#x2010;term neurological and neuropsychiatric manifestations of post&#x2010;COVID&#x2010;19 syndrome: a meta&#x2010;analysis. J Neurol Sci. 2022;434:120162. doi:10.1016/j.jns.2022.120162</Citation></Reference><Reference><Citation>Kappelmann N, Dantzer R, Khandaker GM. Interleukin&#x2010;6 as potential mediator of long&#x2010;term neuropsychiatric symptoms of COVID&#x2010;19. Psychoneuroendocrinology. 2021;131:105295. doi:10.1016/j.psyneuen.2021.105295</Citation></Reference><Reference><Citation>Voitsidis P, Gliatas I, Bairachtari V, et al. Insomnia during the COVID&#x2010;19 pandemic in a Greek population. Psychiatry Res. 2020;289:113076. doi:10.1016/j.psychres.2020.113076</Citation></Reference><Reference><Citation>Shi L, Lu ZA, Que JY, et al. Prevalence of and risk factors associated with mental health symptoms among the general population in China during the coronavirus disease 2019 pandemic. JAMA Network Open. 2020;3:e2014053. doi:10.1001/jamanetworkopen.2020.14053</Citation></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non&#x2010;hospitalized adults. Nature Med. 2022;28:1706&#x2010;1714. doi:10.1038/s41591-022-01909-w</Citation></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co&#x2010;occurrence, and evolution of long&#x2010;COVID features: a 6&#x2010;month retrospective cohort study of 273,618 survivors of COVID&#x2010;19. PLoS Med. 2021;18:e1003773. doi:10.1371/journal.pmed.1003773</Citation></Reference><Reference><Citation>Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID&#x2010;19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398:2093&#x2010;2100. doi:10.1016/S0140-6736(21)02249-2</Citation></Reference><Reference><Citation>Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F. SARS&#x2010;CoV&#x2010;2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022;7:141. doi:10.1038/s41392-022-00997-x</Citation></Reference><Reference><Citation>Ministry of Health, Labour and Welfare. Preliminary results of the 5th Antibody Retention Survey (Resident Survey). 2023. 116th Meeting (8 February https://www.mhlw.go.jp/content/10900000/001055259.pdf</Citation></Reference><Reference><Citation>Huang L, Li X, Gu X, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID&#x2010;19: a longitudinal cohort study. Lancet Respir Med. 2022;10:863&#x2010;876. doi:10.1016/S2213-2600(22)00126-6</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>